Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "insulin"

115 News Found

Alarming rise in diabetes amongst children and adolescents in India
News | November 14, 2021

Alarming rise in diabetes amongst children and adolescents in India

The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue


NPPA fixes ceiling price for anti-diabetic generic medicines
Policy | October 26, 2021

NPPA fixes ceiling price for anti-diabetic generic medicines

A total of 12 generic medicines have been included in the list


Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
News | October 25, 2021

Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22

The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively


Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
News | October 25, 2021

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Lilly to transfer rights of two diabetes drugs to Cipla in India
Drug Approval | October 04, 2021

Lilly to transfer rights of two diabetes drugs to Cipla in India

Lilly will continue to maintain its existing operating model for the remaining portfolio of products


WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
Biotech | September 26, 2021

U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations

The company does not expect the outcome of this inspection to impact its plans


Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


Acute therapies drive overall pharma growth in July: Ind-Ra
News | August 30, 2021

Acute therapies drive overall pharma growth in July: Ind-Ra

The segment delivered strong sales growth of 20% YoY


Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Drug Approval | August 28, 2021

Japan approves AstraZeneca’s Forxiga for chronic kidney disease

Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options